The effect of intravenous iloprost on pulmonary artery hypertension after paediatric congenital heart surgery

dc.contributor.authorOnan, Ismihan Selen
dc.contributor.authorOzturk, Erkut
dc.contributor.authorYildiz, Okan
dc.contributor.authorAltin, Husnu Firat
dc.contributor.authorOdemis, Ender
dc.contributor.authorErek, Ersin
dc.date.accessioned2023-02-21T12:34:12Z
dc.date.available2023-02-21T12:34:12Z
dc.date.issued2016-01-01
dc.description.abstractOBJECTIVES: To investigate the effects of intravenous iloprost on pulmonary artery hypertension (PAH) in infants undergoing congenital heart surgery. METHODS: In this prospective, randomized study, the study group (n = 15) received a continuous infusion of iloprost (2.0 ng/kg/min) that was delivered immediately after weaning from cardiopulmonary bypass and continued for 72 h postoperatively. Patients in the control group (n = 12) were managed conventionally. The groups were compared in terms of postoperative data, including systolic and mean pulmonary artery (PA) pressures, PA/systemic pressure ratio, lactate level, PAH crisis, ventilation time, reintubation and lengths of intensive care unit (ICU) and hospital stay. Transthoracic echocardiography was used to assess PA pressures at 1 day, 7 days and 30 days after surgery. RESULTS: No mortality occurred. PAH crisis occurred in 2 (16.6\%) patients in the control group and 4 (26.7\%) patients in the study group (P = 0.53). Postoperative PA pressures and PA/systemic pressure ratios were similar between the groups (P > 0.05). The durations of ICU (P = 0.40) and hospital (P = 0.98) stays were similar between the groups. Echocardiographic studies demonstrated a significant decrease in postoperative PA pressures in the control (P = 0.001) and study (P = 0.0001) groups. However, no significant change was observed between the groups (P > 0.05). The Tukey multiple comparison test showed a significant decrease in PA pressures at each follow-up in both groups (P < 0.05). CONCLUSIONS: Intravenous iloprost demonstrated no additional benefit over the conventional management of infants with PAH after repair of intracardiac defects. Clinicians may prefer other alternative agents in infants with a high risk of PAH crisis.
dc.description.issue2
dc.description.issueFEB
dc.description.pages194-199
dc.description.volume22
dc.identifier.doi10.1093/icvts/ivv325
dc.identifier.urihttps://hdl.handle.net/11443/1688
dc.identifier.urihttp://dx.doi.org/10.1093/icvts/ivv325
dc.identifier.wosWOS:000372420100013
dc.publisherOXFORD UNIV PRESS
dc.relation.ispartofINTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY
dc.subjectCongenital heart surgery
dc.subjectPulmonary arterial hypertension
dc.subjectIntravenous iloprost
dc.titleThe effect of intravenous iloprost on pulmonary artery hypertension after paediatric congenital heart surgery
dc.typeArticle

Files

Collections